 |
|
|
Important Notice: The Forum does not endorse any medical
product or therapy. ALL medications and supplements
should be taken ONLY under the supervision of a physician,
due to the possibility of side-effects, drug interactions,
etc.
|
Drug:
|
EPO
|
|
Mode of action:
|
Neuroprotectant
|
|
Phase:
|
POC Completed
|
|
Company:
|
Max Planck Institute
|
|
Note:
|
Small but significant effect as cognitive enhancer add-on in
small Phase 2 study
|
Ehrenreich H, Hinze-Selch D, Stawicki S, Aust C,
Knolle-Veentjer S, Wilms S, Heinz G, Erdag S, Jahn H, Degner
D, Ritzen M, Mohr A, Wagner M, Schneider U, Bohn M, Huber M,
Czernik A, Pollmächer T, Maier W, Sirén AL, Klosterkötter J,
Falkai P, Rüther E, Aldenhoff JB, Krampe H. Improvement of
cognitive functions in chronic schizophrenic patients by
recombinant human erythropoietin. Mol Psychiatry . 2007 Feb
1 ; 12(2):206-20. Abstract
|
|
|
|
|
Text Size 
See our most recent Schizophrenia Bulletin theme Webinar: